Free Trial

BioXcel Therapeutics (BTAI) Insider Trading & Ownership

BioXcel Therapeutics logo
$0.64
-0.02 (-3.02%)
(As of 11/1/2024 ET)

BioXcel Therapeutics (NASDAQ:BTAI) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
28.70%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
5
Amount Of
Insider Selling
(Last 12 Months)
$234,910.45
Get BTAI Insider Trade Alerts

Want to know when executives and insiders are buying or selling BioXcel Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

BTAI Insider Buying and Selling by Quarter

BioXcel Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/3/2024Matthew T WileyInsiderSell6,272$0.55$3,449.60  
10/3/2024Richard I SteinhartCFOSell7,175$0.55$3,946.25  
9/16/2024Frank YoccaInsiderSell355$0.69$244.95  
9/16/2024Richard I SteinhartCFOSell356$0.69$245.64  
9/16/2024Vimal MehtaCEOSell1,982$0.69$1,367.58  
6/17/2024Frank YoccaInsiderSell372$1.28$476.16  
6/17/2024Vimal MehtaCEOSell2,134$1.28$2,731.52  
6/4/2024Vimal MehtaCEOSell126,014$1.63$205,402.82  
4/4/2024Richard I SteinhartCFOSell1,069$2.63$2,811.47  
4/4/2024Vimal MehtaCEOSell5,268$2.62$13,802.16  
4/4/2024Vincent O'neillInsiderSell165$2.62$432.30  
(Data available from 1/1/2013 forward)

BTAI Insider Trading Activity - Frequently Asked Questions

The list of insiders at BioXcel Therapeutics includes Frank Yocca, Javier Rodriguez, Krishnan Nandabalan, Matthew T Wiley, Richard I Steinhart, Vimal Mehta, and Vincent O'neill. Learn more on insiders at BTAI.

28.70% of BioXcel Therapeutics stock is owned by insiders. Learn more on BTAI's insider holdings.

The following insiders have sold BTAI shares in the last 24 months: Frank Yocca ($1,520,115.76), Javier Rodriguez ($48,766.20), Krishnan Nandabalan ($2,029,310.26), Matthew T Wiley ($3,449.60), Richard I Steinhart ($183,491.36), Vimal Mehta ($2,252,379.08), and Vincent O'neill ($432.30).

Insiders have sold a total of 425,355 BioXcel Therapeutics shares in the last 24 months for a total of $6,037,944.56 sold.

BioXcel Therapeutics Key Executives

  • Dr. Vimal D. Mehta Ph.D. (Age 62)
    Founder, CEO, President, & Director
    Compensation: $1.76M
  • Mr. Javier Rodriguez (Age 51)
    Senior VP, Chief Legal Officer & Corporate Secretary
    Compensation: $638.88k
  • Mr. Matthew Wiley (Age 51)
    Senior VP & Chief Commercial Officer
    Compensation: $620.12k
    1 recent trades
  • Mr. Richard I. Steinhart MBA (Age 67)
    Senior VP & CFO
    Compensation: $404k
    2 recent trades
  • Dr. Frank D. Yocca Ph.D. (Age 67)
    Senior VP & Chief Scientific Officer
    Compensation: $452.58k
  • Dr. Vincent J. O'Neill B.Sc. (Age 55)
    M.D., M.R.C.P., Executive VP and Chief of Product Development & Medical Officer
    Compensation: $510.17k
  • Dr. Chetan D. Lathia Ph.D.
    Senior VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs
  • Dr. Robert Risinger M.D.
    Chief Medical Officer - Neuroscience


This page (NASDAQ:BTAI) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners